9:20 am Wednesday January 15th 2025
Dendrimer Nanoparticles (DEP) Enable Targeted Precision Delivery and Customized Biodistribution for Cancer Radiotheranostics
mce-anchorJeremy Paull, Vice President, Development & Regulatory Affairs, Starpharma Holdings Ltd.
DEP dendrimer nanparticles are a versatile, clinically validated platform that enables targeted and precision delivery and customized biodistribution profiles for cancer radiotheranostics. DEP dendrimers can be tailored in size to address shortcomings of small molecule and large antibody targeting, and can carry different payloads and different targeting moieties. The biodistribution and efficacy of targeted DEP dendrimer radiotheranostics show a favorable biodistribution profile, with rapid blood clearance and significant tumor accumulation, coupled with anticancer activity in models of human disease.
The Targeted Radioligand Therapies track at the PepTalk meeting on January 14–15, 2025 will explore the latest advancements in targeted radioligand therapies (RLTs) for cancer treatment. The meeting will focus on: Innovative targeting mechanisms, Emerging targets, Pre-targeting strategies, Clinical and commercial considerations, and Supply chain and quality control challenges.
RLTs are a promising cancer treatment that combines the specificity of targeted molecules with the potency of radioisotopes. This approach can precisely eliminate cancer cells while minimizing damage to healthy tissue
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Jeremy Paull, Vice President, Development & Regulatory Affairs, Starpharma Holdings Ltd.
(20min delay)